Nicole Germino
Stock Analyst at Truist Securities
(1.63)
# 3,024
Out of 4,831 analysts
22
Total ratings
26.32%
Success rate
-6.23%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Nicole Germino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CATX Perspective Therapeutics | Maintains: Buy | $21 → $10 | $2.32 | +331.97% | 2 | Apr 7, 2025 | |
| YMAB Y-mAbs Therapeutics | Maintains: Buy | $21 → $18 | $3.84 | +368.75% | 2 | Mar 5, 2025 | |
| INSM Insmed | Maintains: Buy | $105 → $108 | $65.50 | +64.89% | 8 | Feb 21, 2025 | |
| SGMO Sangamo Therapeutics | Maintains: Buy | $7 → $5 | $0.45 | +1,003.27% | 5 | Jan 23, 2025 | |
| ASMB Assembly Biosciences | Downgrades: Hold | $132 → $24 | $12.61 | +90.33% | 3 | Oct 24, 2022 | |
| FBRX Forte Biosciences | Downgrades: Hold | n/a | $6.82 | - | 2 | Sep 3, 2021 |
Perspective Therapeutics
Apr 7, 2025
Maintains: Buy
Price Target: $21 → $10
Current: $2.32
Upside: +331.97%
Y-mAbs Therapeutics
Mar 5, 2025
Maintains: Buy
Price Target: $21 → $18
Current: $3.84
Upside: +368.75%
Insmed
Feb 21, 2025
Maintains: Buy
Price Target: $105 → $108
Current: $65.50
Upside: +64.89%
Sangamo Therapeutics
Jan 23, 2025
Maintains: Buy
Price Target: $7 → $5
Current: $0.45
Upside: +1,003.27%
Assembly Biosciences
Oct 24, 2022
Downgrades: Hold
Price Target: $132 → $24
Current: $12.61
Upside: +90.33%
Forte Biosciences
Sep 3, 2021
Downgrades: Hold
Price Target: n/a
Current: $6.82
Upside: -